J. Hao

Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.

W. Aberer, J. Bernstein, H. Farkas, 2017, The journal of allergy and clinical immunology. In practice.

Preventing Hereditary Angioedema Attacks in Children Using Cinryze®: Interim Efficacy and Safety Phase 3 Findings

E. Aygören‐Pürsün, I. Martínez-Saguer, J. Schranz, 2017, International Archives of Allergy and Immunology.

Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema

W. Aberer, M. Vardi, H. Farkas, 2021, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study.

Moshe Y. Vardi, K. Eto, M. Hide, 2020, Allergology international : official journal of the Japanese Society of Allergology.

[EFFICACY, PHARMACOKINETICS, AND SAFETY OF ICATIBANT FOR THE TREATMENT OF JAPANESE PATIENTS WITH AN ACUTE ATTACK OF HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].

Moshe Y. Vardi, K. Eto, M. Hide, 2018, Arerugi = [Allergy].

Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study

J. Bernstein, W. Lumry, M. Maurer, 2021, Allergy.

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks

J. Bernstein, W. Lumry, M. Maurer, 2020, Allergy.